Edit
Fougera Pharmaceuticals, Inc.
http://www.convergencepharma.com/Last activity: 24.09.2014
Active - Reference to Afternic
Acquired by Biogen
Novel analgesics based on state dependent ion channel pharmacology and medicinal chemistry platform.
Cambridge, UK
Novel analgesics based on state dependent ion channel pharmacology and medicinal chemistry platform.
Cambridge, UK
Investors 1
| Date | Name | Website |
| - | New Leaf V... | nlvpartner... |
Mentions in press and media 3
| Date | Title | Description |
| 24.09.2014 | SF startup gets $1.4M to develop non-opioid pain meds | The sodium ion channel that SiteOne’s targeting – Nav1.7 – “is validated as a target for pain treatment by human genetic conditions,” the company said, which is why it’s attracting a lot of interest as a therapeutic target. Indeed, Cambridg... |
| 05.10.2010 | Convergence Pharmaceuticals Raises $35.4M in Series A Financing | Convergence Pharmaceuticals, a Cambridge, UK-based biotechnology company focused on the development of novel analgesics, has received a $35.4m Series A private equity financing. Investors include New Leaf Venture Partners, Apposite Capital ... |
| - | SF startup gets $1.4M to develop non-opioid pain meds | SiteOne Therapeutics, a San Francisco startup in the pain meds and pain diagnostics arena, has raised $1.5 million in an initial equity round. On top of that, it just secured a $1.4 million Phase II SBIR grant from the NIH. This early fundi... |